Although RRAS2 is overexpressed in the majority of breast cancers, independent of their pathological classification, clinical grade, and molecular classification, the overexpression is highest and more frequent in TNBC, the type of BC for which there are fewer effective therapeutic options nowadays due to its unresponsiveness to anti-hormone therapies and anti-HER2 antibodies. The gene discussed is ERBB2; the disease is breast carcinoma.